AlloVir, Inc. (NASDAQ:ALVR – Get Rating) CEO Diana Brainard sold 4,536 shares of the firm’s stock in a transaction on Thursday, May 18th. The shares were sold at an average price of $4.21, for a total value of $19,096.56. Following the completion of the transaction, the chief executive officer now owns 916,628 shares of the company’s stock, valued at approximately $3,859,003.88. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Diana Brainard also recently made the following trade(s):
- On Wednesday, April 19th, Diana Brainard sold 8,408 shares of AlloVir stock. The shares were sold at an average price of $3.71, for a total value of $31,193.68.
AlloVir Trading Up 1.9 %
Shares of NASDAQ:ALVR opened at $4.19 on Monday. The stock’s 50-day moving average price is $4.07 and its two-hundred day moving average price is $5.53. AlloVir, Inc. has a 12-month low of $3.17 and a 12-month high of $10.29. The firm has a market cap of $392.14 million, a price-to-earnings ratio of -2.10 and a beta of 0.72.
Institutional Trading of AlloVir
Wall Street Analysts Forecast Growth
A number of analysts recently commented on ALVR shares. Morgan Stanley decreased their price objective on AlloVir from $27.00 to $20.00 and set an “overweight” rating on the stock in a research note on Friday, January 27th. SVB Leerink decreased their price objective on AlloVir from $25.00 to $19.00 and set an “outperform” rating on the stock in a research note on Monday, January 23rd. Finally, SVB Securities increased their price objective on AlloVir from $16.00 to $19.00 in a research note on Wednesday, April 26th.
AlloVir Company Profile
Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus.
- Get a free copy of the StockNews.com research report on AlloVir (ALVR)
- MarketBeat Week in Review – 5/15 – 5/19
- Applied Materials: Cracks In The Chip Recovery Or Time To Buy?
- Deere & Company Rallies On Farm Equipment Boom, Bullish Outlook
- How Many Roth IRAs Can You Have?
- Why You Should Consider Buying Nvidia Ahead Of Earnings
Receive News & Ratings for AlloVir Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AlloVir and related companies with MarketBeat.com's FREE daily email newsletter.